Strides Pharma Science Limited (STAR.NS)
INR 634.75
(-2.33%)
INR 634.75
(-2.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.76 Billion INR | 354.45% |
| 2022 | 5.02 Billion INR | 430.99% |
| 2021 | -1.34 Billion INR | -107.45% |
| 2020 | 7.25 Billion INR | 67.5% |
| 2019 | 4.86 Billion INR | 10.59% |
| 2018 | 2.99 Billion INR | -20.25% |
| 2017 | 4.25 Billion INR | -44.68% |
| 2016 | 5.33 Billion INR | 42.47% |
| 2015 | 4.72 Billion INR | 138.38% |
| 2014 | 2.44 Billion INR | 16.55% |
| 2013 | 2.05 Billion INR | -61.21% |
| 2012 | 5.28 Billion INR | -0.13% |
| 2011 | 5.59 Billion INR | 33.74% |
| 2010 | 3.86 Billion INR | 158.52% |
| 2009 | 2.1 Billion INR | -75.21% |
| 2008 | 3.82 Billion INR | 252.57% |
| 2007 | 1.04 Billion INR | 24.27% |
| 2006 | 1.4 Billion INR | 19.47% |
| 2005 | 1.16 Billion INR | 11.16% |
| 2004 | 1.06 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.16 Billion INR | 8.57% |
| 2024 Q2 | 2.47 Billion INR | 9.55% |
| 2023 FY | - INR | 354.45% |
| 2023 Q4 | 2.29 Billion INR | 44.75% |
| 2023 Q3 | 1.58 Billion INR | 7.43% |
| 2023 Q2 | 1.47 Billion INR | 5.71% |
| 2023 Q1 | 1.39 Billion INR | -1.49% |
| 2022 FY | - INR | 430.99% |
| 2022 Q2 | 304.88 Million INR | 76.13% |
| 2022 Q4 | 1.41 Billion INR | 498.49% |
| 2022 Q3 | 237.05 Million INR | -22.25% |
| 2022 Q1 | 173.1 Million INR | -71.84% |
| 2021 Q3 | -130.98 Million INR | 64.45% |
| 2021 Q1 | -609.43 Million INR | -151.27% |
| 2021 FY | - INR | -107.45% |
| 2021 Q2 | -368.49 Million INR | 39.54% |
| 2021 Q4 | 614.77 Million INR | 569.36% |
| 2020 Q2 | 1.62 Billion INR | -18.51% |
| 2020 Q3 | 1.82 Billion INR | 12.77% |
| 2020 Q4 | 1.18 Billion INR | -35.04% |
| 2020 Q1 | 1.99 Billion INR | 636.3% |
| 2020 FY | - INR | 67.5% |
| 2019 Q1 | 1.11 Billion INR | 89.85% |
| 2019 FY | - INR | 10.59% |
| 2019 Q4 | -371.28 Million INR | -119.56% |
| 2019 Q3 | 1.89 Billion INR | 60.71% |
| 2019 Q2 | 1.18 Billion INR | 6.27% |
| 2018 Q3 | 1.2 Billion INR | 29.55% |
| 2018 Q2 | 933.7 Million INR | 14.03% |
| 2018 Q1 | 818.8 Million INR | -20.59% |
| 2018 FY | - INR | -20.25% |
| 2018 Q4 | 585.31 Million INR | -51.61% |
| 2017 FY | - INR | -44.68% |
| 2017 Q4 | 1.03 Billion INR | -26.79% |
| 2017 Q3 | 1.4 Billion INR | -6.23% |
| 2017 Q2 | 1.5 Billion INR | 20.47% |
| 2017 Q1 | 1.24 Billion INR | -50.47% |
| 2016 Q1 | 1.51 Billion INR | -5.28% |
| 2016 Q4 | 2.51 Billion INR | 21.59% |
| 2016 Q3 | 2.07 Billion INR | 0.33% |
| 2016 Q2 | 2.06 Billion INR | 35.75% |
| 2016 FY | - INR | 42.47% |
| 2015 Q2 | 755.87 Million INR | -23.32% |
| 2015 Q1 | 985.8 Million INR | 66.07% |
| 2015 FY | - INR | 138.38% |
| 2015 Q4 | 1.6 Billion INR | -30.32% |
| 2015 Q3 | 2.3 Billion INR | 204.65% |
| 2014 Q3 | 666.79 Million INR | 8.75% |
| 2014 Q2 | 613.14 Million INR | 51.69% |
| 2014 Q1 | 404.21 Million INR | 0.0% |
| 2014 FY | - INR | 16.55% |
| 2014 Q4 | 593.62 Million INR | -10.97% |
| 2013 FY | - INR | -61.21% |
| 2012 FY | - INR | -0.13% |
| 2011 FY | - INR | 33.74% |
| 2010 FY | - INR | 158.52% |
| 2009 FY | - INR | -75.21% |
| 2008 FY | - INR | 252.57% |
| 2007 FY | - INR | 24.27% |
| 2006 FY | - INR | 19.47% |
| 2005 FY | - INR | 11.16% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 681.59 Million INR | -452.333% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -28867.99% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 39.12% |
| FDC Limited | 3.38 Billion INR | -11.204% |
| Gufic Biosciences Limited | 1.48 Billion INR | -154.287% |
| Hikal Limited | 2.69 Billion INR | -39.835% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 45.134% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -44.429% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -1209.796% |
| Medico Remedies Limited | 129.09 Million INR | -2816.232% |
| Nectar Lifesciences Limited | 1.53 Billion INR | -145.162% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -1549.916% |
| RPG Life Sciences Limited | 1.28 Billion INR | -193.771% |
| Sequent Scientific Limited | 549.8 Million INR | -584.736% |
| Shilpa Medicare Limited | 2.58 Billion INR | -45.468% |
| Sigachi Industries Limited | 883.39 Million INR | -326.159% |
| Themis Medicare Limited | 562.6 Million INR | -569.149% |
| Unichem Laboratories Limited | 742.35 Million INR | -407.126% |
| Venus Remedies Limited | 711.8 Million INR | -428.895% |
| Wanbury Limited | 985.49 Million INR | -282.011% |
| ZIM Laboratories Limited | 462.09 Million INR | -714.695% |
| Lupin Limited | 36.96 Billion INR | 89.817% |
| Innova Captab Limited | 1.66 Billion INR | -125.658% |
| Ind-Swift Limited | 1.06 Billion INR | -253.469% |
| Bajaj HealthCare Limited | 406.23 Million INR | -826.718% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 93.907% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 233.409% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -59.737% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -2051.91% |
| Morepen Laboratories Limited | 1.72 Billion INR | -118.122% |
| Laurus Labs Limited | 8 Billion INR | 52.977% |
| Aarti Drugs Limited | 3.24 Billion INR | -15.885% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 45.144% |
| Alembic Limited | 1.11 Billion INR | -237.234% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 60.853% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 66.813% |
| Vaishali Pharma Limited | 31.71 Million INR | -11771.843% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 3.702% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -1063.878% |
| Jubilant Pharmova Limited | 8 Billion INR | 52.977% |
| Eris Lifesciences Limited | 6.98 Billion INR | 46.115% |
| Windlas Biotech Limited | 781.72 Million INR | -381.589% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 97.279% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -180.251% |
| Orchid Pharma Limited | 1.41 Billion INR | -165.272% |
| Albert David Limited | 1.04 Billion INR | -260.111% |
| Hester Biosciences Limited | 539.47 Million INR | -597.848% |
| Sakar Healthcare Limited | 393.26 Million INR | -857.281% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 19.51% |
| Procter & Gamble Health Limited | 3.07 Billion INR | -22.453% |
| Divi's Laboratories Limited | 25.43 Billion INR | 85.196% |
| Mankind Pharma Limited | 28.09 Billion INR | 86.6% |
| Neuland Laboratories Limited | 4.74 Billion INR | 20.713% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 59.671% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 93.304% |
| Wockhardt Limited | 1.08 Billion INR | -248.581% |
| Bal Pharma Limited | 345.59 Million INR | -989.342% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 95.735% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -154.537% |
| Alkem Laboratories Limited | 24.19 Billion INR | 84.44% |
| Valiant Laboratories Limited | 12.73 Million INR | -29452.398% |
| Ajanta Pharma Limited | 12.56 Billion INR | 70.039% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -3185.548% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -8235.392% |
| Granules India Limited | 8.6 Billion INR | 56.244% |
| Medicamen Biotech Limited | 245.66 Million INR | -1432.476% |
| Ipca Laboratories Limited | 13.29 Billion INR | 71.693% |
| Brooks Laboratories Limited | 41.72 Million INR | -8921.952% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -774.945% |
| Piramal Enterprises Limited | -3.86 Billion INR | 197.503% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 89.247% |
| NATCO Pharma Limited | 18.79 Billion INR | 79.97% |
| Suven Life Sciences Limited | -992.78 Million INR | 479.206% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 4650.727% |
| Indoco Remedies Limited | 2.64 Billion INR | -42.222% |
| Alpa Laboratories Limited | 229.96 Million INR | -1537.095% |
| Lasa Supergenerics Limited | -65.08 Million INR | 5884.696% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 200.89% |